Putnam Investments’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $1.06B | Buy |
1,210,735
+24,329
| +2% | +$20M | 1.4% | 11 |
|
|
2023
Q3 | $976M | Buy |
1,186,406
+17,085
| +1% | +$13.4M | 1.48% | 10 |
|
|
2023
Q2 | $840M | Buy |
1,169,321
+4,004
| +0.3% | +$3.09M | 1.24% | 15 |
|
|
2023
Q1 | $958M | Buy |
1,165,317
+47,784
| +4% | +$36M | 1.54% | 10 |
|
|
2022
Q4 | $806M | Buy |
1,117,533
+13,700
| +1% | +$10.1M | 1.41% | 10 |
|
|
2022
Q3 | $760M | Sell |
1,103,833
-7,670
| -0.7% | -$4.83M | 1.45% | 9 |
|
|
2022
Q2 | $657M | Buy |
1,111,503
+16,292
| +1% | +$10.6M | 1.18% | 17 |
|
|
2022
Q1 | $765M | Sell |
1,095,211
-248,392
| -18% | -$157M | 1.16% | 15 |
|
|
2021
Q4 | $849M | Buy |
1,343,603
+849
| +0.1% | +$522K | 1.21% | 13 |
|
|
2021
Q3 | $813M | Buy |
1,342,754
+404,567
| +43% | +$251M | 1.26% | 13 |
|
|
2021
Q2 | $524M | Buy |
938,187
+282,535
| +43% | +$143M | 0.82% | 29 |
|
|
2021
Q1 | $310M | Buy |
655,652
+231,463
| +55% | +$113M | 0.52% | 63 |
|
|
2020
Q4 | $205M | Sell |
424,189
-298,334
| -41% | -$161M | 0.36% | 79 |
|
|
2020
Q3 | $404M | Buy |
722,523
+23,989
| +3% | +$14.5M | 0.8% | 32 |
|
|
2020
Q2 | $436M | Buy |
698,534
+24,483
| +4% | +$13.9M | 0.93% | 25 |
|
|
2020
Q1 | $329M | Buy |
674,051
+197,393
| +41% | +$81.4M | 0.86% | 26 |
|
|
2019
Q4 | $179M | Buy |
476,658
+474,138
| +18,815% | +$160M | 0.37% | 77 |
|
|
2019
Q3 | $699K | Buy |
2,520
+21
| +0.8% | +$6.21K | ﹤0.01% | 786 |
|
|
2019
Q2 | $782K | Sell |
2,499
-33,054
| -93% | -$11M | ﹤0.01% | 780 |
|
|
2019
Q1 | $14.6M | Buy |
35,553
+28,548
| +408% | +$11.8M | 0.03% | 282 |
|
|
2018
Q4 | $2.62M | Buy |
7,005
+5,986
| +587% | +$2.19M | 0.01% | 590 |
|
|
2018
Q3 | $412K | Sell |
1,019
-121
| -11% | -$46.1K | ﹤0.01% | 955 |
|
|
2018
Q2 | $393K | Hold |
1,140
| – | – | ﹤0.01% | 966 |
|
|
2018
Q1 | $393K | Hold |
1,140
| – | – | ﹤0.01% | 976 |
|
|
2017
Q4 | $429K | Sell |
1,140
-224,510
| -99% | -$90.9M | ﹤0.01% | 973 |
|
|
2017
Q3 | $101M | Buy |
225,650
+426
| +0.2% | +$203K | 0.23% | 116 |
|
|
2017
Q2 | $111M | Buy |
225,224
+223,625
| +13,985% | +$97.9M | 0.26% | 106 |
|
|
2017
Q1 | $620K | Hold |
1,599
| – | – | ﹤0.01% | 1079 |
|
|
2016
Q4 | $587K | Sell |
1,599
-100
| -6% | -$38K | ﹤0.01% | 1102 |
|
|
2016
Q3 | $683K | Sell |
1,699
-100
| -6% | -$40.1K | ﹤0.01% | 1086 |
|
|
2016
Q2 | $628K | Buy |
1,799
+99
| +6% | +$38.1K | ﹤0.01% | 1169 |
|
|
2016
Q1 | $613K | Buy |
1,700
+100
| +6% | +$41.2K | ﹤0.01% | 1206 |
|
|
2015
Q4 | $869K | Hold |
1,600
| – | – | ﹤0.01% | 1188 |
|
|
2015
Q3 | $744K | Sell |
1,600
-100
| -6% | -$53.7K | ﹤0.01% | 1238 |
|
|
2015
Q2 | $867K | Sell |
1,700
-108
| -6% | -$52.7K | ﹤0.01% | 1248 |
|
|
2015
Q1 | $816K | Buy |
1,808
+19
| +1% | +$8.05K | ﹤0.01% | 1236 |
|
|
2014
Q4 | $734K | Sell |
1,789
-1,190
| -40% | -$468K | ﹤0.01% | 1230 |
|
|
2014
Q3 | $1.07M | Sell |
2,979
-203
| -6% | -$68K | ﹤0.01% | 1185 |
|
|
2014
Q2 | $899K | Buy |
3,182
+2
| +0.1% | +$593 | ﹤0.01% | 1208 |
|
|
2014
Q1 | $955K | Buy |
3,180
+103
| +3% | +$31.7K | ﹤0.01% | 1212 |
|
|
2013
Q4 | $847K | Sell |
3,077
-1,537
| -33% | -$442K | ﹤0.01% | 1244 |
|
|
2013
Q3 | $1.44M | Buy |
4,614
+77
| +2% | +$20.3K | ﹤0.01% | 1142 |
|
|
2013
Q2 | $1.02M | Buy |
+4,537
| New | +$1.06M | ﹤0.01% | 1211 |
|
Other funds holding REGN
Putnam Investments's REGN Position: Q4 2023 in Review
Putnam Investments increased its Regeneron Pharmaceuticals (REGN) stake by 2.1% in Q4 2023, buying an estimated $20M and bringing the position to 1,210,735 shares worth $1.06B. The position accounts for 1.4% of the portfolio, ranked #11.
Putnam Investments first reported a position in REGN in Q2 2013 and has held it in 43 quarters since. 1,272 funds tracked by Wall St. Rank hold REGN as of Q4 2023.
- Putnam Investments held 1,210,735 shares of Regeneron Pharmaceuticals worth $1.06B as of Q4 2023.
- Putnam Investments bought 24,329 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $20M.
- Regeneron Pharmaceuticals made up 1.4% of Putnam Investments's portfolio in Q4 2023, its #11 holding.
- Putnam Investments first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
- 1,272 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.
Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.